前列腺癌
医学
癌症研究
免疫疗法
免疫系统
肿瘤微环境
细胞毒性
放射性配体
前列腺
癌症免疫疗法
免疫调节
癌症
T细胞
靶向治疗
细胞
前列腺癌
单克隆抗体
免疫学
肿瘤科
肿瘤细胞
PD-L1
易普利姆玛
临床试验
受体
肿瘤免疫学
免疫检查点
作者
Carolina Sciortino,Amedeo Nuzzo,Marco Stellato,Mélanie Claps,Alessandro Rametta,Valentina Guadalupi,Eleonora Gusmaroli,Simone Rota,Federica Mascaro,Patrizia Giannatempo,Matteo Zimatore,Marco Maccauro,Veronica Huber,Elena Verzoni,Giuseppe Procopio
标识
DOI:10.1080/14737140.2026.2657914
摘要
Introduction Metastatic castration-resistant prostate cancer (mCRPC) remains a therapeutic challenge despite advances in systemic treatments. Prostate-specific membrane antigen (PSMA) – targeted radioligand therapy (RLT) with 177Lu-PSMA-617 has emerged as an effective strategy, and increasing evidence suggests that its activity may extend beyond direct cytotoxicity to the modulation of the tumor immune microenvironment.Areas covered A narrative literature review was conducted using the PubMed database to identify relevant studies published up to January 2026. This review summarizes preclinical and clinical evidence on the immunomodulatory effects of PSMA-targeted RLT. We discuss how 177Lu-PSMA-617 influences immune cell populations, induces immunogenic cell death, and interacts with key microenvironmental factors such as hypoxia, vascularization, and PSMA heterogeneity. The role of alternative radioligands, including alpha-emitters and fibroblast activation protein – targeted agents, is also examined.Expert opinion PSMA-targeted RLT represents a promising immune-priming modality in mCRPC, but its clinical impact is limited by tumor and microenvironmental heterogeneity. Biomarker-driven patient selection, optimized dosimetry, and rational combination strategies with immunotherapy will be essential to fully exploit its immunomodulatory potential and to achieve durable clinical benefit.
科研通智能强力驱动
Strongly Powered by AbleSci AI